Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...

The randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.

Here is a list of top stocks that are likely to take focus in today's trading session.

Take a look at top stocks that are likely to stay in limelight in today's trading.

In April, Lupin formed a joint venture with Japan’s Yoshindo for biosimilars. It is also in talks with other local drug makers for alliance...

Lupin had also increased research and development spending to Rs 958.28 crore in FY'14 as compared to Rs 770.85 crore in the FY'13.

Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...